Consistent with our data, others have suggested that SERDs can differ in their ability to degrade ER in ER+ breast cancer cell lines, and that this correlates with a partial agonist phenotype and poorer anti-proliferative activity in the cell lines where degradation is compromised (43). The gene discussed is ESR1; the disease is breast cancer.